* A study analyzed 177 Asian patients' responses to various biologics and tofacitinib over several trials, revealing that secukinumab, ixekizumab, guselkumab, and risankizumab were more effective than other treatments, especially in specific body areas.
* Although treatment responses varied by location, both the head and neck and lower extremities showed slower overall improvement, indicating the need for more studies with larger groups to better assess treatment efficacy across different body regions.